ValueRich

Avenue Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) diseases and pain management. The company's lead product candidate is an intravenous (IV) formulation of tramadol, designed to manage moderate to moderately severe postoperative pain in a hospital setting as an alternative to conventional opioids. Avenue is also advancing a clinical-stage pipeline that includes BAER-101, a selective GABA-A receptor modulator for CNS disorders, and AJ201, a first-in-class treatment for spinal and bulbar muscular atrophy (Kennedy’s Disease). Originally incorporated as ValueRich, Inc., the company transitioned into the life sciences sector in 2015 through a strategic rebranding led by Fortress Biotech. Avenue Therapeutics is headquartered in Miami, Florida, and is publicly traded on the NASDAQ exchange.